Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.47M Sell
11,472
-300
-3% -$35.1K 0.66% 17
2026
Q1
$1.42M Sell
11,772
-55
-0.5% -$6.35K 0.75% 17
2025
Q4
$1.24M Sell
11,827
-89
-0.7% -$8.36K 0.66% 17
2025
Q3
$1M Buy
11,916
+304
+3% +$25K 0.54% 23
2025
Q2
$919K Buy
11,612
+6,981
+151% +$555K 0.53% 20
2025
Q1
$416K Hold
4,631
0.26% 61
2024
Q4
$461K Buy
+4,631
New +$477K 0.28% 55

Other funds holding MRK

Sylvest Advisors's MRK Position: Q2 2026 in Review

Sylvest Advisors reduced its Merck (MRK) stake by 2.5% in Q2 2026, selling an estimated $35.1K and leaving 11,472 shares worth $1.47M. The position accounts for 0.66% of the portfolio, ranked #17.

Sylvest Advisors first reported a position in MRK in Q4 2024 and has held it in 7 quarters since. 1,411 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Sylvest Advisors held 11,472 shares of Merck worth $1.47M as of Q2 2026.
  • Sylvest Advisors sold 300 Merck shares in Q2 2026, an estimated $35.1K.
  • Merck made up 0.66% of Sylvest Advisors's portfolio in Q2 2026, its #17 holding.
  • Sylvest Advisors first reported a position in Merck in Q4 2024 and has held it in 7 quarters since.
  • 1,411 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Sylvest Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.